- Home
- SOLV vs INCY Comparison
SOLV vs INCY Comparison
Compare SOLV & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOLV
- INCY
- Stock Information
- Founded
- SOLV 2023
- INCY 1991
- Country
- SOLV United States
- INCY United States
- Employees
- SOLV N/A
- INCY N/A
- Industry
- SOLV
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- SOLV
- INCY Health Care
- Exchange
- SOLV NYSE
- INCY Nasdaq
- Market Cap
- SOLV 12.7B
- INCY 13.4B
- IPO Year
- SOLV N/A
- INCY 1993
- Fundamental
- Price
- SOLV $73.58
- INCY $68.46
- Analyst Decision
- SOLV Hold
- INCY Hold
- Analyst Count
- SOLV 10
- INCY 20
- Target Price
- SOLV $80.29
- INCY $73.81
- AVG Volume (30 Days)
- SOLV 993.3K
- INCY 2.0M
- Earning Date
- SOLV 08-07-2025
- INCY 07-29-2025
- Dividend Yield
- SOLV N/A
- INCY N/A
- EPS Growth
- SOLV N/A
- INCY N/A
- EPS
- SOLV 2.18
- INCY 0.10
- Revenue
- SOLV $8,308,000,000.00
- INCY $4,413,226,000.00
- Revenue This Year
- SOLV $4.11
- INCY $13.29
- Revenue Next Year
- SOLV N/A
- INCY $10.47
- P/E Ratio
- SOLV $33.78
- INCY $705.59
- Revenue Growth
- SOLV 1.29
- INCY 17.13
- 52 Week Low
- SOLV $47.16
- INCY $53.56
- 52 Week High
- SOLV $85.92
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- SOLV N/A
- INCY 56.95
- Support Level
- SOLV N/A
- INCY $67.57
- Resistance Level
- SOLV N/A
- INCY $71.29
- Average True Range (ATR)
- SOLV 0.00
- INCY 1.98
- MACD
- SOLV 0.00
- INCY -0.13
- Stochastic Oscillator
- SOLV 0.00
- INCY 61.55
About SOLV SOLVENTUM CORP
Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.